Fengyun Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fengyun Su has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Arul M. Chinnaiyan
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
95 shared publications - Xuhong Cao
University of Michigan 1 Ann Arbor, MI
95 shared publications - Marcin P. Cieslik
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
66 shared publications - Rahul Mannan
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, USA
66 shared publications - Rui Wang
Michigan Center for Translational Pathology, University of Michigan
66 shared publications - Jing Hu
Department of Pathology, Qilu Hospital, Shandong University, Jinan, China
65 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Table S6. Data from the CRISPR screen in Myc-CaP cells treated with TAK-243 + IFN-β.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Table S6. Data from the CRISPR screen in Myc-CaP cells treated with TAK-243 + IFN-β.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Table S5. Data from the CRISPR screen in Myc-CaP cells treated with TAK-243 + IFN-γ.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Table S5. Data from the CRISPR screen in Myc-CaP cells treated with TAK-243 + IFN-γ.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S1. High expression of UBA1 is associated with low levels of intratumoral CD8+ T cells and predictive of ICB resistance and poor survival in ICB cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S1. High expression of UBA1 is associated with low levels of intratumoral CD8+ T cells and predictive of ICB resistance and poor survival in ICB cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Table S1. UBA1 protein expression and levels of intratumoral CD8+ T cells in tumor samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Table S1. UBA1 protein expression and levels of intratumoral CD8+ T cells in tumor samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S4. UBA1 inhibition synergizes with anti-PD-1 therapy to control tumor growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S4. UBA1 inhibition synergizes with anti-PD-1 therapy to control tumor growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S7. UBA1 inactivation upregulates interferon signaling via stabilizing JAK1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S7. UBA1 inactivation upregulates interferon signaling via stabilizing JAK1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S5. UBA1 inactivation upregulates interferon signaling.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S5. UBA1 inactivation upregulates interferon signaling.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Table S4. Sequences of primers used in RT-qPCR in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Table S4. Sequences of primers used in RT-qPCR in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S10. UBA1 inactivation upregulates interferon signaling in human cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S10. UBA1 inactivation upregulates interferon signaling in human cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S3. UBA1 diminishes intratumoral functional T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Supplementary Figure S3. UBA1 diminishes intratumoral functional T cells.